Physician profile
Jon M Johnson
NPI 1598765497
$2,997.77
in general payments reported to CMS, 2019-2025
36 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $611 · 2021: $699 · 2022: $406 · 2023: $342 · 2024: $175 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $397.93 | 2019-2023 | Ozempic |
| Amgen INC. | $371.91 | 2019-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.63 | 2020-2024 | Ofev |
| Abbott Laboratories | $209.96 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $193.71 | 2019-2024 | Farxiga |
| Lilly USA, LLC | $172.06 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $158.48 | 2023 | Xarelto |
| Abbvie INC. | $148.18 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $141.66 | 2022-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $114.08 | 2022-2024 | Hetlioz, Fanapt |
| Eisai INC. | $97.07 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $84.09 | 2019-2022 | |
| Astellas Pharma US INC | $68.40 | 2019-2022 | |
| Radius Health, INC. | $54.51 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $53.35 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $50.64 | 2019-2021 | |
| Amarin Pharma, INC. | $37.81 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $35.74 | 2019-2021 | |
| Neuronetics, INC. | $35.02 | 2019 | |
| Sanofi-Aventis U.S. LLC | $28.16 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $27.81 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $24.60 | 2019 | |
| Dexcom, INC. | $24.41 | 2021-2022 | |
| Pfizer INC. | $24.35 | 2019 | |
| Redhill Biopharma INC. | $23.48 | 2021 | |
| Sunovion Pharmaceuticals INC. | $21.73 | 2022 | |
| Medtronic, INC. | $20.03 | 2025 | Intellis Adaptivestim |
| Scilex Pharmaceuticals INC. | $18.48 | 2021 | |
| Kaleo, INC. | $17.59 | 2019 | |
| Viatris Specialty LLC | $17.22 | 2025 | Yupelri |
| Exact Sciences Corporation | $16.88 | 2023 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $16.23 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.55 | 2021 | |
| Glaxosmithkline, LLC. | $12.65 | 2022 | |
| Grifols USA, LLC | $11.50 | 2020 | |
| Bardy Diagnostics, INC. | $8.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.